Categories
News

CESPE welcomes professor Hristo Svilenov

We are excited to announce that professor Hristo Svilenov has joined CESPE as an academic member. With the onboarding of prof. Svilenov, we further strengthen our capabilities in the field of biopharmaceutical manufacturing.

Hristo Svilenov is a professor of biopharmaceutical manufacturing technology and formulation in the Laboratory of General Biochemistry and Physical Pharmacy at Ghent University. Before moving to Ghent, he was postdoc with Prof. Johannes Buchner at the Technical University of Munich funded by a fellowship from the Peter und Traudl Engelhorn Foundation and a grant from the Else Kröner-Fresenius Foundation. From 2016 to 2019, he did his PhD sponsored by a Maria Skłodowska-Curie fellowship in the group of Prof. Gerhard Winter at the University of Munich. For his research, Dr. Svilenov received several prizes like the Carl Wilhelm Scheele Award from the German Pharmaceutical Society (DPhG) or the Abbvie Award for the best doctoral thesis. He is a pharmacist by training.

Hristo Svilenov is working on different aspects of the development, manufacturing, and formulation of biotherapeutics. A strong research focus is on the application of novel analytical techniques and biophysical methods to design better therapeutic proteins and formulations.

Categories
CESPE Conference 2022 News Program

Manufacturing Innovations for a Sustainable (Bio)Pharmaceutical Industry

Conference opening, introductions and keynote

9h00: Registration

9h30
Welcome & conference opening
Rik Van de Walle, Rector UGent

9h40
Introduction to CESPE
Prof. Thomas De Beer, CESPE Director

10h00
Flanders R&D policies for better health and care – Towards Recovery Resilience
Kathleen D’Hondt, Policy Analyst, Department Economy, Science and Innovation – Flemish Government

10h15
Keynote ‘Healthcare Innovation: the crossroads of HealthTech and the (bio)pharmaceutical ecosystem’
Ann Van Gysel, CEO Medvia

10h45
Break (posters & exhibition booths)

Chemical drug substance manufacturing of the future

11h05
Drug Substance Manufacturing in 2030 – adaptive, connected & sustainable
Yves Vancleemput, Director Business Development, Janssen Pharmaceutica

11h20
The Future will flow, more and more in the pharmaceutical sector
Prof. Chris Stevens, UGent

11h35
Design of Sustainable Pharmaceutical Processes with Artifcial Intelligence
Maarten Dobbelaere, UGent

Biopharmaceuticals: a fast growing pipeline

11h50
Setting up a large scale clinical and commercial CAR-T manufacturing HUB in Ghent
Birk Vanderweeën, General Manager Europe, Legend Biotech

12h10
Networking lunch (posters & exhibition booths)

13h25
Continuous manufacturing of antibodies: the inevitable step towards sustainable drug manufacturing
Koen Dierckx, CEO SimAbs

13h40
Discovery and selection of therapeutic antibodies with drug-like properties
Prof. Hristo Svilenov, UGent

13h55
An academic’s journey to spin-out commercialization of a new manufacturing technology: continuous pharmaceutical lyophilization
Prof. Thomas De Beer, UGent & RheaVita

Towards efficient Drug Product Development & Controlled Manufacturing

14h10
Challenges and opportunities in drug product development
Fanny Stauffer, Drug Product Expert, UCB

14h30
Linking material proporties to their behavior during processing
Prof. Chris Vervaet, UGent

Process simulation & sustainable systems engineering as key element for future proof pharmaceutical manufacturing

14h45
Advanced process simulation for smart manufacturing process development, scale-up and operation
Wim Audenaert, CEO & Co-founder AM-Team

15h00
Sustainability Assessment in the pharmaceutical sector
dr. Lieselot Boone, UGent

15h15
Break (posters & exhibition booths)

(Bio)pharmaceutical manufacturing; staying ahead of what’s next

15h45
Panel discussion
Ann Van Gysel, CEO Medvia
Claire Skentelbery, Director General EuropaBio
Yves Vancleemput, Director Business Development, Janssen Pharmaceutica
Birk Vanderweeën, General Manager Europe, Legend Biotech
Prof. Thomas De Beer, CESPE Director
(moderation: Tineke Van hooland)

16h30
Pech Kucha presentations

Closing

17h45
Closing word
Sofie Bracke, Executive Councillor for Economy, Port and Sports, City of Ghent

Wouter De Soete, Manager CESPE
Christoph Portier, CESPE Operations Manager

Networking reception & Dinner

18h00 – 22h00
(posters & exhibition booths)


On this page you will find all the updates considering the program of our CESPE conference on Manufacturing Innovations for a Sustainable (Bio)Pharmaceutical Industry. At this event, there will be a mix of senior industry leaders, policy makers, academics and startups. There will be a variety of talks on chemical drug substance, drug product and biotech manufacturing, providing insights in both industrial and academic state-of-the-art. There will also be ample opportunities to network with all participants. 

What’s in it for you?
You will:

  • Have access to state-of-the-art science in the field of chemical drug substance, drug product and biotech manufacturing
  • Get to know groundbreaking and disruptive manufacturing technologies
  • Expand your professional network 
  • Learn more about our new facilities planned at Tech Lane Ghent Science Park, including cleanrooms to handle potent APIs 
  • Have the latest insights in the new Master in Pharmaceutical Engineering, unique in Flanders and launched in September ’22. 
  • Have discussion opportunities with talented PhD and postdoctoral researchers through interactive poster sessions
  • Learn about access to young talent through various master thesis opportunities

Categories
CESPE Conference 2022 News Program

Keynote speaker: Dr. Ann Van Gysel

We are excited to announce Dr. Ann Van Gysel as keynote speaker at our CESPE Conference on Manufacturing Innovations for a Sustainable (Bio)Pharmaceutical Industry on September 15th in Ghent! Dr. Van Gysel was recently appointed as CEO of the spearhead cluster MEDVIA. In her keynote, she will focus on the current trends in healthcare and the (bio)pharmaceutical landscape.

Ann Van Gysel has always been passionate about innovation in healthcare. She started out as a biologist and received her PhD in molecular biology from the University of Gent. She acquired post-graduate degrees in Business Management and Marketing and Communications. In 2009, she joined FlandersBio as Managing Director. During her three-year tenure, she doubled the number of members, putting Flanders on the international map as a one of the major biotech hubs. In 2011, Ann founded Turnstone Communications, a consultancy agency providing communications and marketing services to healthcare, life sciences and pharmaceutical organizations in Belgium and abroad. She was the founder of the digital life sciences news platform BioVox.eu, sharing Belgian innovations with national and international professionals. Since January 2022 she has been the CEO of MEDVIA, a public-private partnership founded by the Flemish Government to support innovation in healthcare focusing on biotech, medtech and digital health.

Categories
CESPE Conference 2022 News Registration

Conference registration

We are pleased to announce that registrations for the CESPE conference on Manufracturing Innovations for a Sustainable (Bio)Pharmaceutical Industry have been opened.

Registrations and payments can be made through our Congrezzo platform: https://congrezzo.ugent.be/cespe_conference2022

Registration fees are €200 for industry (30% reduction for members) and €50 for academia (free for members).
For the networking dinner, a supplement of €75 is charged.
These early bird rates apply until August 31st.

Deadline for registration is September 8.

For information on sponsorships and exhibition booths, as well as general questions considering the conference and CESPE, feel free to contact Dr. Christoph Portier (Christoph.Portier@UGent.be) or Dr. Wouter De Soete (Wouter.DeSoete@UGent.be). 

Categories
CESPE Conference 2022 News

CESPE Conference 2022

CESPE is pleased to announce its yearly conference on Thursday September 15, 2022 focusing on Manufacturing Innovations for a Sustainable (Bio)Pharmaceutical Industry. This event will cover both drug substance and drug product manufacturing innovations, demonstrating the position of Flanders and Belgium as global leaders in (bio)pharmaceutical manufacturing. During this physical event in Ghent, you will have the opportunity to network with our academic members, industrial partners and policy makers. Therefore, this event is perfectly suited for senior scientists, industrial decision makers and policy makers active within the ecosystem.

Stay tuned for more information on the program and registration!

For further information on booths and sponsorships, feel free to contact Christoph Portier (Christoph.Portier@UGent.be) or Wouter De Soete (Wouter.DeSoete@UGent.be).

Categories
News

2 PhD Positions to develop a Predictive Framework enabling Real-Time Release Testing in Solid Dosage Manufacturing

2 PhD Positions to develop a Predictive Framework enabling Real-Time Release Testing in Solid Dosage Manufacturing

Overview

This PhD project aims to develop a knowledge-based predictive framework for dissolution testing to enable real-time release testing (RTRt) in solid dosage manufacturing. The research will be conducted in close cooperation with pharmaceutical companies and the UGent research accelerator Centre of Excellence in Sustainable Pharmaceutical Engineering and Manufacturing (CESPE). The research outcome will be published in important scientific journals.

Traditionally, RTRt frameworks are developed by individual companies and partnering research institutions leading to a costly and resource-intensive process. Moreover, the development requires a thorough process understanding as well as controls embedded in the production processes. In this project, a predictive framework for dissolution testing will be developed using material, process, and PAT data from continuous direct compression process. This project presents a unique opportunity to work at the academia-industry interface on a very important and relevant topic to the pharmaceutical industry. A range of formulations and knowledge from multiple pharmaceutical companies involved in the project will lead to development of a generic and better predictive framework enabling RTRt.

The project currently has two open positions for PhD candidates: a PhD project with an Experimental focus and a PhD project with a mathematical modeling focus. The researcher with an experimental focus will get an in-depth scientific understanding, hands-on experience of direct compression based manufacturing and gain expertise in practical aspects of dissolution test development applicable to an industrial working environment. The researcher with a modeling focus will apply different modeling approaches of developing in vitro predictive dissolution models based on product and process understanding. Hence, a predictive dissolution modeling framework will be developed to support product development within the space explored during formulation and process optimization and as surrogate tests in a regulatory filing towards RTRt.

Profiles

Experimental research focus:

  1. Master’s degree in pharmaceutical sciences, physical chemistry, or a related discipline
  2. Experience in dissolution testing of pharmaceutical dosage forms.
  3. Experience with various analytical techniques (DSC, XRD, IR, TGA, DVS, HPLC).
  4. Experience in multivariate data analysis is desirable.

Mathematical modeling research focus:

  1. Master’s degree in bioengineering, chemical engineering, and process engineering or a related discipline
  2. Experience with the development of numerical methods
  3. Experience with mechanistic and data-driven modeling methodologies
  4. Experience in Python and/or MATLAB is desirable.
  5. Candidates must have a strong interest in both experiments and theoretical modeling

More information
For further information, please contact:

Pharmaceutical engineering research group (Ghent University) Faculty of Pharmaceutical Sciences

Prof. dr. Ashish Kumar (Ashish.Kumar@UGent.be)

LPPAT research group (Ghent University) Faculty of Pharmaceutical Sciences

Prof. dr. Thomas De Beer (Thomas.DeBeer@UGent.be)

Laboratory of Pharmaceutical Technology (Ghent University) Faculty of Pharmaceutical Sciences

Prof. dr. Chris Vervaet (Chris.Vervaet@UGent.be), Prof. dr. Valérie Vanhoorne (Valerie.Vanhoorne@UGent.be)

How to apply

You have to use the online application tool available here or by sending an email to Ashish.Kumar@UGent.be to provide your CV with names of three references, motivation letter and transcripts of your bachelor and master studies.

Application deadline and start date

The position is available immediately and will remain open until it is filled. While the start date is flexible, the target is to start from Feb 2022.

Categories
News

2 Vacant PhD Positions on Continuous Pharmaceutical Freeze-Drying

2 PhD positions in Pharmaceutical Manufacturing Innovation with Focus on Continuous Pharmaceutical Freeze-Drying

Overview

The general goal of these PhD research projects is to further innovate in a continuous freeze-drying technology for (bio)pharmaceuticals and explore its potential as an enabler for different pharmaceutical products.

Topic 1: The evaluation of different energy supply systems for the continuous & controlled
(mechanistic based) freeze-drying of biopharmaceutical unit doses.

Topic 2: Continuous freeze-drying as an enabling technology for different types of pharmaceutical products (e.g., lipid nano-particle based products, highly concentrated protein formulations, vaccines, cold chain distributed products, etc.)
The research projects may be conducted in close cooperation between Ghent University (Belgium) and
pharmaceutical companies and equipment manufacturers. The PhD project will be executed in Ghent, Belgium. The research outcome will be published in important scientific journals.

Profile

  1. Master’s degree in Pharmaceutical Drug Development, Industrial Pharmacy, Pharmaceutical Engineering, Bio-science Engineering, Chemical Engineering or a related discipline.
  2. Experience with pharmaceutical technology is desirable.
  3. Candidates must have a strong interest in biopharmaceutical product development manufacturing innovation, analysis and data-analysis.

The PhD project will be guided by the Pharmaceutical Process Analytics & Technology research group (Faculty of Pharmaceutical Sciences, Ghent University, Prof. Dr. Thomas De Beer), and will be in collaboration with the Pharmaceutical Engineering Research Group (Prof. Dr. Ashish Kumar).

Pharmaceutical Process Analytics & Technology research group (Ghent University) Faculty of Pharmaceutical Sciences
Prof. Dr. T. De Beer – Thomas.DeBeer@UGent.be – +32-9-2648097

How to apply

Please send your CV with names of three references, motivation letter and transcripts of your bachelor and master studies to Thomas.DeBeer@UGent.be

Application deadline

Please apply before February 28th, 2022

Categories
News

Ghent University takes the lead in the production of tomorrow’s medicines

Belgium has an excellent position in the development of new medicines. ‘To continue to play that leading role, we also need to focus on innovation in drug production,’ says Professor Thomas De Beer.

With the CESPE Innovation Accelerator, Ghent University offers an answer to the need for top research infrastructure for innovation in pharmaceutical production technology. This is necessary to further anchor Belgium’s leading position in the field of drug development research and to guarantee its production in our region.

Need for innovation in pharmaceutical production

‘If you look at pharmaceutical manufacturing innovation over the last decades, it hasn’t kept up with the speed of drug development. Innovation in the pharmaceutical sector primarily focuses on the development of medicines. But the increasing complexity of medicines and their supply needs also requires innovation in production technology,’ says Professor Thomas De Beer. He is director of CESPE, the Center of Excellence for Sustainable Pharmaceutical Engineering & Manufacturing at Ghent University, which is the basis of the new innovation accelerator for production technology in the pharmaceutical sector.

‘Innovation in the pharmaceutical sector primarily focuses on the development of medicines. But the increasing complexity of medicines and their supply needs also requires innovation in production technology.’ Professor Thomas De Beer.

cleanroom
Researcher in a cleanroom, © Ghent University, photo Hilde Christiaens

‘Unlike other sectors in the manufacturing industry, pharmaceutical products are often developed before it is clear how they can be produced on a large scale in a competitive, sustainable and flexible way. By linking the development of a medicine at an early stage to the development of the production process, you shorten the lead time,’ explains Professor De Beer.

‘The Corona pandemic has also increased the need for agile production technologies. Just think of the supply of intermediate substances in the event of an abruptly rising demand or local production of critical medicines, and the associated cold chain distribution at -80°C of certain vaccines. This requires new technologies and we will research and develop them in the new CESPE center in collaboration with the industry,’ says Wouter De Soete, manager of CESPE at Ghent University.

Unique research infrastructure

The CESPE Innovation Accelerator will include cleanrooms, lab and office space as well as a (bio)pharmtech incubator. ‘This combination of research infrastructure in the field of production innovation is unique in Belgium. With this we make a huge difference, not only for academic research but also for industry,’ emphasizes Professor De Beer.

‘This research infrastructure in the field of production innovation is unique in Belgium. With this we make a huge difference, not only for academic research but also for industry.’ Professor De Beer.

cleanroom
Researchers in a cleanroom, © Ghent University, photo Hilde Christiaens

There are strict requirements for the production of medicines. You have to create the right conditions for researchers and for the products you work with. Thanks to the modular and flexible layout of the cleanrooms and lab areas, large companies, start-ups and research institutions can perform tests and collaborate under optimal conditions. This is the only way to create the right environment for innovation.’

The center also provides the necessary space to accommodate spin-offs resulting from this innovative research. ‘We strongly believe that cross-fertilization between industry and academia will lead to innovative production technologies. In the field of production technology within the pharmaceutical sector, we want to become the reference point, both for research and training of the right profiles. For that reason, we will start with a new master in pharmaceutical engineering in the academic year 2022-2023. This combination of pharmaceutical and engineering skills is much needed in the sector to realize innovation. By focusing on that, we are firmly convinced that this will lead to new start-ups. We also want to offer them the necessary support in the CESPE center to start up and grow.’

‘The main goal of CESPE is to be the leading innovation hub in Europe for the end-to-end pharmaceutical production of tomorrow’s medicines,’ according to Wouter De Soete. ‘That means that we examine the entire drug production chain, from development to its supply to the market, and examine how we can model and optimize it as best as possible. For this we have to call on different expertise. Just think of experts in the field of big data, AI, automation and robotization, energy-efficient production,…’ According to De Soete, the center in Zwijnaarde will be a game changer for the pharmaceutical industry in Flanders, which will also provide a lot of jobs.

More information

Thomas De Beer, thomas.debeer@ugent.be

Wouter De Soete, wouter.desoete@ugent.be

Categories
Research groups

Pharmaceutical Engineering

Field of Expertise:
Pharmaceutical Engineering

Given the complexity and increasing diversity of products and technologies in (bio-)pharmaceuticals processing, it is clear that there will be no “one size fits all” solution for new process development and manufacturing requirements. The research in Pharmaceutical Engineering (PharmaEng) group involves development and application of a digital twin of equipment, processes, and the environment, where functions and properties are treated using various mechanistic frameworks. The research group aims to apply these digital twins to deliver solutions covering all the three aspects of pharmaceutical process development – product design, process design, and process improvement. Modeling frameworks based on first-principles such as DEM, FEM, CFD, and PBM in combination with kinetic, thermodynamic models will be used to design and optimize the system to deliver drug substances and products with desired physical properties.

Our research areas include both classical batch and continuous processing unit operations. Within these fields, we have an extensive expertise in following domains:

  • Process equipment design and optimization
  • Process and equipment scale-up
  • Detailed modeling of pharmaceutical processes for mechanistic insights
  • Advanced pharmaceutical manufacturing control strategy
Categories
Team

Dr. Christoph Portier

Project Manager, Operations

Ghent University
Centre of Excellence in Sustainable Pharmaceutical Engineering
Faculty of Pharmaceutical Sciences
Campus Heymans
Ottergemsesteenweg 460
B-9000 Gent, Belgium

Christoph.Portier@UGent.be

+32 9 264 81 18

Christoph Portier is Project Manager, Operations at the Centre of Excellence in Sustainable Pharmaceutical Engineering and Manufacturing (CESPE). His focus is project portfolio management, supporting academic CESPE members during the project proposal phase, and facility management of the CESPE Innovation Accelerator. After obtaining his Master in Drug Development and Advanced Master in Industrial Pharmacy, he joined the Laboratory of Pharmaceutical Technology as PhD researcher. His PhD research, in collaboration with Janssen, focused on increased process and formulation understanding during continuous twin screw wet granulation and downstream processing. During his PhD, he was (co)author of 14 peer reviewed publications. Additionally, he is experienced in hot melt granulation, hot melt extrusion and development of nasal spray suspensions. He is also active as reviewer for Pharmaceutics.

Categories
Team

Dr. An Van Den Bulcke

business developer

Ghent University
Faculty of Sciences
Department of Organic and Macromolecular Chemistry
Krijgslaan 281, S4
B-9000 Gent, Belgium

a.vandenbulcke@ugent.be

+32 9 264 44 62

An Van Den Bulcke holds a Ph.D in Chemistry (Polymer Synthesis) and has an industrial career in product development and R&D management. In 2011 she started as Business Developer at ChemTech, the Chemistry Business and Valorisation cluster at Ghent University.

As Senior Business Developer, dr. An Van Den Bulcke is responsible for the coordination and facilitation of commercialisation of new research findings to market-ready technologies and products, specifically for biomedical markets (pharma, biotech, diagnostics), personal care (cosmetics) and biomaterials markets. She is the focal point for industrial collaborations and builds a relevant network of life science companies interested in chemical expertise or novel (patented) technologies to boost their innovations. In this way, she is involved i.a.:

  • Managing the portfolio of collaborations with academic and industrial partners
  • Building and managing a strategic IP portfolio
  • Prospecting licensing opportunities and negotiating licensing deals
  • Creation of spin-off companies

Specialties: research & innovation management – technology transfer – project portfolio management – out-licensing – intellectual property – technology & business development

Categories
Team

Prof. Dr. Ludwig Cardon

principal investigator

Ghent University
Faculty of Engineering and Architecture
Centre for Polymer and Material Technologies
Department of Materials, Textiles and Chemical Engineering
Technologiepark Zwijnaarde 130
B-9052 Gent, Belgium

Ludwig.Cardon@UGent.be

+32 9 331 03 90

Prof. Dr. Ludwig Cardon became Mechanical Engineer in 1988 and joined the University College of Ghent, Belgium since 1990. He received his Ph.D. degree in Engineering in 2006 from the Birmingham City University, UK. Since 2006, he is the head of the Centre for Polymer & Material Technologies CPMT and professor at the faculty of Applied Engineering Sciences of the University College of Ghent. He is co-founder of the rapid prototyping research group (RPT), now integrated in CPMT. His actual research interests mainly include high-tech polymer technology/processing and RPT for several applications such as technical parts, biobased polymers, micro moulding, bioengineering and biomedical applications.

Categories
Team

Prof. Dr. Ashish Kumar

PRINCIPAL INVESTIGATOR

Ghent University
Faculty of Pharmaceutical Sciences
Laboratory of Pharmaceutical Process Analytical Technology
Campus Heymans
Ottergemsesteenweg 460
B-9000 Gent, Belgium

Ashish.Kumar@UGent.be

+32 9 264 59 37

Prof. dr. ir. Ashish Kumar has been working in the field of Pharmaceuticals and biologics development since 2007 in both academic and industrial set-up. Before joining Ghent University, he worked as a Senior Process Engineer at the drug product development division of Janssen Pharmaceutica, Belgium. He obtained his Ph.D. from Ghent University in 2015, for research on the experimental and model-based analysis of twin-screw wet granulation for continuous solid-dosage manufacturing in pharmaceutical production. Before, he obtained a Professional Doctorate in Engineering as a Designer in Bioprocess Engineering from the Technical University of Delft in 2011, and worked for Janssen Pharmaceutica, in Leiden, The Netherlands and Dr. Reddy’s Laboratories in India. His research interests lie in the area of developing insights regarding constitutive mechanisms of various pharmaceutical processes by combining experimental and mechanistic modeling frameworks to provide innovative solutions. The Pharma Eng research group he leads focuses on the model-based design of pharmaceutical and biopharmaceutical manufacturing equipment and processes for innovative drug products.

Categories
Team

Prof. Dr. Hristo Svilenov

principal investigator

Ghent University
Faculty of Pharmaceutical Sciences
Laboratory of General Biochemistry and Physical Pharmacy
Campus Heymans
Ottergemsesteenweg 460
B-9000 Gent, Belgium

Hristo.Svilenov@UGent.be

Hristo Svilenov is a professor of biopharmaceutical manufacturing technology and formulation in the Laboratory of General Biochemistry and Physical Pharmacy at Ghent University. Before moving to Ghent, he was postdoc with Prof. Johannes Buchner at the Technical University of Munich funded by a fellowship from the Peter und Traudl Engelhorn Foundation and a grant from the Else Kröner-Fresenius Foundation. From 2016 to 2019, he did his PhD sponsored by a Maria Skłodowska-Curie fellowship in the group of Prof. Gerhard Winter at the University of Munich. For his research, Dr. Svilenov received several prizes like the Carl Wilhelm Scheele Award from the German Pharmaceutical Society (DPhG) or the Abbvie Award for the best doctoral thesis. He is a pharmacist by training.

Hristo Svilenov is working on different aspects of the development, manufacturing, and formulation of biotherapeutics. A strong research focus is on the application of novel analytical techniques and biophysical methods to design better therapeutic proteins and formulations.

Categories
Team

Prof. Dr. Valérie Vanhoorne

principal investigator

Ghent University
Faculity of Pharmaceutical Sciences
Laboratory of Pharmaceutical Technology
Campus Heymans
Ottergemsesteenweg 460
B-9000 Gent, Belgium

Valerie.Vanhoorne@UGent.be

+32 9 264 80 91

Valérie Vanhoorne graduated in 2011 with great distinction as a pharmacist (Master of Science in Drug Development) from Ghent University (UGent) and started her PhD under supervision of Prof. Jean-Paul Remon and Prof. Chris Vervaet in the Laboratory of Pharmaceutical Technology (UGent). In 2016, she obtained her PhD in Pharmaceutical Sciences studying continuous agglomeration technologies. She continued working in the lab as a postdoctoral researcher focusing on innovative manufacturing processes for oral solid dosage forms. Initially, she worked as a postdoctoral researcher in close collaboration with Janssen Pharmaceutica (Belgium) on the development of predictive empirical models for continuous direct compression and platform formulations for continuous twin screw granulation. Later on, as doctor-assistant, she also worked on patient-tailored dosage forms and performed a research stay at the University of Düsseldorf working on roller compaction. Her current research line will focus on formulation and process development of continuous manufacturing processes and on personalization of dosage forms (via 3D-printing and multi-particulate dosage forms) to meet the needs of specific patient populations.

Categories
Research groups

CADS

Field of Expertise:
Applied Data Sciences

The Centre for Applied Data Science (CADS) has an extensive experience in the field of data sciences, including:

  • Statistical analysis process and R&D data

– Regression analysis and statistical modeling
– Predictive modeling: Machine Learning (neural/boosted tree/boat step forest)
– Multivariate analysis: PCA/Factor Analysis/Clustering
– Time-series analysis

  • Experimental planning using (AI based) Optimal Design of Experiments (DOE)
  • Quality & Process control

Above statistical methods are applied to:
– Monitoring, assessing stability and performance of production processes
– Optimization and validation of measurement systems
– Modeling of industrial processes, determining “Design Space” & optimal process parameter control ranges